

ImmunoCellular Therapeutics' ICT-107 Drug Candidate Featured in CBS Television News Story

Story Calls Vaccine "Promising" Brain Cancer Treatment

LOS ANGELES, CA – June 8, 2011 – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), announced today that ICT-107, its lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), was featured in a story on CBS New York's Channel 2 Newscast titled "Vaccine Could Kill Brain Tumors Using Body's Own Immune System." The story, by CBS' Dr. Max Gomez, a nine-time Emmy Award winning Medical Journalist, called ICT-107 a "promising vaccine" for the treatment of brain cancer. In the story, Dr. Joseph Landolfi, a clinical investigator at New Jersey Neuroscience Institute, noted that "in their Phase I trial, 80% of the patients showed a two-year survival."

The story can be accessed and the video viewed at www.imuc.com, Newsroom, IMUC in the News, click Vaccine for Brain Tumor.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell-based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates; and the risk of obtaining patent coverage for the dendritic cell-based vaccine or that any patents covering this vaccine will provide commercially significant protection for this product candidate. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.